Metabolic reprogramming: The driving force behind cancer drug resistance

IF 2.5 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2025-07-16 DOI:10.1016/j.seminoncol.2025.152392

Amr Ali Mohamed Abdelgawwad El-Sehrawy , Chou-Yi Hsu , Ali G. Alkhathami , Muktesh Chandra , Tina Saeed Basunduwah , H. Malathi , Jitendra Narayan Senapati , Apurav Gautam , Mundher Kadhem , Hatif Abdulrazaq Yasin

{"title":"Metabolic reprogramming: The driving force behind cancer drug resistance","authors":"Amr Ali Mohamed Abdelgawwad El-Sehrawy , Chou-Yi Hsu , Ali G. Alkhathami , Muktesh Chandra , Tina Saeed Basunduwah , H. Malathi , Jitendra Narayan Senapati , Apurav Gautam , Mundher Kadhem , Hatif Abdulrazaq Yasin","doi":"10.1016/j.seminoncol.2025.152392","DOIUrl":null,"url":null,"abstract":"<div><div>Metabolic reprogramming enables stress adaptation of cancer cells to treatment and is a primary causative force of drug resistance. Dysregulation of glucose, amino acid, and lipid metabolism supplies energy, biosynthetic precursors, and redox balance, promoting survival in the treated tumor. These processes are coordinated by oncogenic signaling, loss of tumor suppressors, and regulatory non-coding RNAs, which promote cancer stemness, immune evasion, and resistance to apoptosis. This review examines the mechanisms by which central metabolic pathways, particularly glycolysis, glutamine metabolism, and fatty acid synthesis, are altered to facilitate drug resistance in various types of cancer. Additionally, we report on novel therapeutic approaches that exploit such metabolic weaknesses to prevent therapy resistance and enhance clinical outcomes. Future directions emphasize the need for advanced metabolic profiling to personalize treatment approaches and the clinical translation of promising preclinical findings to overcome this significant obstacle in cancer therapy.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 5","pages":"Article 152392"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775425000843","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Metabolic reprogramming enables stress adaptation of cancer cells to treatment and is a primary causative force of drug resistance. Dysregulation of glucose, amino acid, and lipid metabolism supplies energy, biosynthetic precursors, and redox balance, promoting survival in the treated tumor. These processes are coordinated by oncogenic signaling, loss of tumor suppressors, and regulatory non-coding RNAs, which promote cancer stemness, immune evasion, and resistance to apoptosis. This review examines the mechanisms by which central metabolic pathways, particularly glycolysis, glutamine metabolism, and fatty acid synthesis, are altered to facilitate drug resistance in various types of cancer. Additionally, we report on novel therapeutic approaches that exploit such metabolic weaknesses to prevent therapy resistance and enhance clinical outcomes. Future directions emphasize the need for advanced metabolic profiling to personalize treatment approaches and the clinical translation of promising preclinical findings to overcome this significant obstacle in cancer therapy.

查看原文本刊更多论文

代谢重编程：癌症耐药性背后的驱动力

代谢重编程使癌细胞能够适应治疗的压力，是耐药性的主要致病力。葡萄糖、氨基酸和脂质代谢失调提供能量、生物合成前体和氧化还原平衡，促进治疗肿瘤的生存。这些过程是由致癌信号、肿瘤抑制因子的缺失和调节非编码rna协调的，这些非编码rna促进癌症的发生、免疫逃避和对细胞凋亡的抵抗。这篇综述探讨了中枢代谢途径，特别是糖酵解、谷氨酰胺代谢和脂肪酸合成被改变以促进各种类型癌症耐药的机制。此外，我们报告了利用这种代谢弱点来预防治疗耐药性和提高临床结果的新治疗方法。未来的方向强调需要先进的代谢分析来个性化治疗方法和临床前研究结果的临床转化，以克服癌症治疗中的这一重大障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.